Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

by Ysios Capital

Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the Neuraxpharm Group (“Neuraxpharm”), a leading E...

Read more

Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

by Minoryx Therapeutics

​Presentation highlights reduction in cerebral lesion progression and the risk of developing cerebral ALD in AMN patients based on MRI and plasma biomarker data.

Read more

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

by Minoryx Therapeutics

Published data highlights therapeutic potential for all forms of X-ALD as well as other neurodegenerative and neuroinflammatory diseases

Read more

Minoryx inicia el ensayo de fase II/III del tratamiento para la adrenomieloneuropatía

by Minoryx Therapeutics

El primer paciente con esta enfermedad rara que ha iniciado el tratamiento con MIN-102 ha sido en el Hospital Vall d'Hebron de Barcelona. El estudio, denominado ADVANCE, reclutará en total a 100 paci...

Read more

Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102

by Professional Newco

MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need. Orphan drug status for MIN-102 has now been granted by both the FDA and the E...

Read more

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Read more

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream